Coya Therapeutics, Inc. (COYA)
5.01
+0.12
(+2.45%)
USD |
NASDAQ |
Sep 21, 16:00
5.01
0.00 (0.00%)
After-Hours: 20:00
Coya Therapeutics Enterprise Value : 71.53M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 71.53M |
| September 17, 2026 | 68.48M |
| September 16, 2026 | 61.44M |
| September 15, 2026 | 65.90M |
| September 14, 2026 | 65.66M |
| September 11, 2026 | 59.56M |
| September 10, 2026 | 62.85M |
| September 09, 2026 | 64.96M |
| September 08, 2026 | 64.96M |
| September 04, 2026 | 68.48M |
| September 03, 2026 | 63.55M |
| September 02, 2026 | 60.50M |
| September 01, 2026 | 62.61M |
| August 31, 2026 | 63.79M |
| August 28, 2026 | 64.49M |
| August 27, 2026 | 70.82M |
| August 26, 2026 | 71.06M |
| August 25, 2026 | 75.05M |
| August 24, 2026 | 73.17M |
| August 21, 2026 | 71.06M |
| August 20, 2026 | 70.82M |
| August 19, 2026 | 73.40M |
| August 18, 2026 | 72.23M |
| August 17, 2026 | 66.37M |
| August 14, 2026 | 69.18M |
| Date | Value |
|---|---|
| August 13, 2026 | 66.37M |
| August 12, 2026 | 66.84M |
| August 11, 2026 | 69.42M |
| August 10, 2026 | 65.66M |
| August 07, 2026 | 69.65M |
| August 06, 2026 | 64.26M |
| August 05, 2026 | 63.55M |
| August 04, 2026 | 64.02M |
| August 03, 2026 | 60.74M |
| July 31, 2026 | 55.11M |
| July 30, 2026 | 52.53M |
| July 29, 2026 | 47.60M |
| July 28, 2026 | 50.65M |
| July 27, 2026 | 56.87M |
| July 24, 2026 | 56.51M |
| July 23, 2026 | 59.56M |
| July 22, 2026 | 59.33M |
| July 21, 2026 | 63.55M |
| July 20, 2026 | 60.97M |
| July 17, 2026 | 63.32M |
| July 16, 2026 | 64.72M |
| July 15, 2026 | 70.35M |
| July 14, 2026 | 71.06M |
| July 13, 2026 | 70.71M |
| July 10, 2026 | 80.21M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 9.157B |
| Oncolytics Biotech, Inc. | 92.30M |
| Sangamo Therapeutics, Inc. | 51.77M |
| Sarepta Therapeutics, Inc. | 2.381B |
| Anixa Biosciences, Inc. | 80.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.638M |
| Revenue (Quarterly) | 0.2437M |
| Total Expenses (Quarterly) | 6.882M |
| EPS Diluted (Quarterly) | -0.283 |
| Gross Profit Margin (Quarterly) | 98.85% |
| Profit Margin (Quarterly) | -2.72K% |
| Earnings Yield | -19.97% |
| Normalized Earnings Yield | -18.35 |